Skip to main content

Paxarel Disease Interactions

There are 6 disease interactions with Paxarel (acetylcarbromal).

Major

Anxiolytics/sedatives/hypnotics (applies to Paxarel) alcohol intox

Major Potential Hazard, High plausibility. Applicable conditions: Acute Alcohol Intoxication

Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs. The central nervous system depressant effects of these agents may be additive with those of alcohol. Severe respiratory depression and death may occur. Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.

References

  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  3. (2001) "Product Information. Ambien (zolpidem)." sanofi-aventis
  4. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  5. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  6. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  7. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  8. (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
View all 8 references
Major

Anxiolytics/sedatives/hypnotics (applies to Paxarel) depression

Major Potential Hazard, Moderate plausibility.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2001) "Product Information. Ambien (zolpidem)." sanofi-aventis
  3. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  4. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  5. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  6. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  7. (2001) "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical
  8. (2002) "Product Information. Xyrem (sodium oxybate)." Orphan Medical
  9. (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
  10. (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
  11. (2010) "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals
  12. (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
  13. (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
  14. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
View all 14 references
Major

Anxiolytics/sedatives/hypnotics (applies to Paxarel) drug dependence

Major Potential Hazard, High plausibility. Applicable conditions: Alcoholism, Drug Abuse/Dependence

Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms. In patients who have developed tolerance, overdosage can still produce respiratory depression and death. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible. Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents. In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients. After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.

References

  1. Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E (1993) "Tolerance and withdrawal with zolpidem." Lancet, 342, p. 374-5
  2. (2001) "Product Information. Ambien (zolpidem)." sanofi-aventis
  3. Gericke CA, Ludolph AC (1994) "Chronic abuse of zolpidem." JAMA, 272, p. 1721-2
  4. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  5. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  6. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  7. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
View all 7 references
Moderate

Anxiolytics/sedatives/hypnotics (applies to Paxarel) glaucoma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Urinary Retention

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

References

  1. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  2. (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
Moderate

Anxiolytics/sedatives/hypnotics (applies to Paxarel) liver disease

Moderate Potential Hazard, Moderate plausibility.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

References

  1. (2002) "Product Information. Buspar (buspirone)." Bristol-Myers Squibb
  2. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  3. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  4. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  5. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  6. (2001) "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical
  7. (2002) "Product Information. Xyrem (sodium oxybate)." Orphan Medical
  8. (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
  9. (2005) "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America
  10. (2010) "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals
  11. (2011) "Product Information. Intermezzo (zolpidem)." Purdue Pharma LP
  12. (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
  13. (2014) "Product Information. Belsomra (suvorexant)." Merck & Co., Inc
View all 13 references
Moderate

Anxiolytics/sedatives/hypnotics (applies to Paxarel) resp depression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Asphyxia, Pulmonary Impairment, Respiratory Arrest

Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are recommended.

References

  1. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  2. Lheureux P, Debailleul G, De Witte O, Askenasi R (1990) "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol, 9, p. 105-7
  3. Murciano D, Aubier M, Palacios S, Parients R (1990) "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest, 97 Suppl, s51-2
  4. (2001) "Product Information. Ambien (zolpidem)." sanofi-aventis
  5. Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F (1993) "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics, 92, p. 461-3
  6. Greenberg SB, Faerber EN (1990) "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol, 20, p. 287-8
  7. (2001) "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical
  8. (2001) "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc
  9. (2001) "Product Information. Equanil (meprobamate)." Wallace Laboratories
  10. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
  11. (2013) "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group
View all 11 references

Paxarel drug interactions

There are 296 drug interactions with Paxarel (acetylcarbromal).

Paxarel alcohol/food interactions

There is 1 alcohol/food interaction with Paxarel (acetylcarbromal).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.